Sudarshan Pharma Industries Ltd Q4 FY25 results deck summary

Results deck of 2 May 2025, summarised by AI from the filing.

Sudarshan Pharma FY25 revenue ₹505.0 cr, EBITDA ₹39.9 cr, PAT ₹16.0 cr; H2FY25 revenue ₹277.3 cr, EBITDA ₹23.4 cr, PAT ₹10.0 cr.

Key takeaways

1. FY25 revenue FY25 revenue ₹505.0 cr (FY24: ₹463.5 cr, +9.0%); H2FY25 revenue ₹277.3 cr (H2FY24: ₹231.7 cr, +19.6%).
2. FY25 EBITDA FY25 EBITDA ₹39.9 cr (FY24: ₹22.8 cr, +75.0%); H2FY25 EBITDA ₹23.4 cr (H2FY24: ₹14.4 cr, +62.0%).
3. FY25 PAT FY25 PAT ₹16.0 cr (FY24: ₹11.5 cr, +39.3%); H2FY25 PAT ₹10.0 cr (H2FY24: ₹6.6 cr, +51.9%).
4. Margin drivers Company focuses on increasing exports and manufacturing sales and maximizing profit margin on resale of API in local markets.
5. PLI investment Committed investment ₹27 cr for Unit 1 (Vitamin B6) and ₹59.7 cr for Unit 2 (Vitamin B1) under PLI scheme.

Original filing on BSE

Sudarshan Pharma Industries Ltd earnings call, investor presentation and press release summaries

• Q4 FY25: Results deck (2 May 2025)
• Other events: Strategy deck (18 Aug 2026), Strategy deck (14 Aug 2026), Strategy deck (15 May 2026), Strategy deck (31 Jan 2026), Strategy deck (14 Aug 2025)